BioPharm Weekly News Roundup—Week of Oct. 6, 2025

Welcome to the BioPharm International® weekly news roundup for the week of Oct. 6, 2025. In this video feature, the editors highlight each week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week. And be sure to check the links below for more in-depth coverage of each story.

RedHill’s $1.8 million deal licenses FDA-approved Talicia (omeprazole magnesium, amoxicillin and rifabutin) to fight widespread Helicobacter pylori antibiotic resistance and gastric cancer risk in Middle East markets.

Prime editing offers safe, precise genome correction, offering innovative delivery methods that are essential to overcome tissue targeting hurdles like cystic fibrosis.

Big biopharma investment drives cell and gene therapy (CGT) scale, expanding applications beyond oncology and securing infrastructure needed for manufacturing consistency and patient access.

Rentschler Biopharma expands into Japan and South Korea, offering new platforms to accelerate specialized biologics development and manufacturing services in Asia.

Mainstreaming chimeric antigen receptor T cell therapy requires decentralizing care, reforming quality standards, and scaling manufacturing via a pivotal shift to allogeneic processes.

CGT 2.0 requires modular platforms, automation, and collaboration for simultaneous flexibility and scalability, ensuring affordable commercial viability and patient access.